TEVA

Teva Pharma Industries Ltd ADR

TEVA, USA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

https://www.tevapharm.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TEVA
stock
TEVA

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? simplywall.st

Read more →
TEVA
stock
TEVA

Has Teva’s 80% Surge in 2024 Already Priced In Its Turnaround Potential? Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$27.8978

Analyst Picks

Strong Buy

6

Buy

4

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

45.62

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.78

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

5.97 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.09 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

5.20 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

4.50

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 50.25% of the total shares of Teva Pharma Industries Ltd ADR

1.

FMR Inc

(5.0678%)

since

2025/06/30

2.

BlackRock Inc

(4.7351%)

since

2025/06/30

3.

MENORA MIVTACHIM HOLDINGS LIMITED

(3.3556%)

since

2025/06/30

4.

Ion Asset Management Ltd.

(3.3429%)

since

2025/06/30

5.

Phoenix Financial Ltd

(3.2918%)

since

2025/06/30

6.

Harel Insurance Invests & Fin Srvcs Ltd

(2.9107%)

since

2025/06/30

7.

Clal Insurance Enterprises Holdings Ltd

(2.8211%)

since

2025/06/30

9.

Exor Investments (UK) LLP

(2.4545%)

since

2025/06/30

10.

Rubric Capital Management LP

(2.2665%)

since

2025/06/30

11.

PointState Capital LP

(1.8056%)

since

2025/06/30

12.

State Street Corp

(1.507%)

since

2025/06/30

13.

Duquesne Family Office LLC

(1.3921%)

since

2025/06/30

14.

Glenview Capital Management LLC

(1.3794%)

since

2025/06/30

15.

Viking Global Investors LP

(1.0183%)

since

2025/06/30

16.

Geode Capital Management, LLC

(0.8394%)

since

2025/06/30

17.

Bank of America Corp

(0.785%)

since

2025/06/30

18.

Soundwatch Capital LLC

(0.7465%)

since

2025/06/30

19.

Assenagon Asset Management SA

(0.7363%)

since

2025/06/30

20.

Slate Path Capital LP

(0.7227%)

since

2025/06/30

21.

Invesco S&P 500 ETF

(0.6905%)

since

2025/07/31

22.

iShares Core MSCI EAFE ETF

(0.6566%)

since

2025/08/31

23.

Fidelity Contrafund

(0.5807%)

since

2025/07/31

24.

EAFE Equity Index Fund T

(0.4701%)

since

2025/06/30

25.

Strategic Advisers Fidelity Intl

(0.3793%)

since

2025/07/31

26.

iShares MSCI EAFE ETF

(0.3403%)

since

2025/08/31

27.

Fidelity International Index

(0.3384%)

since

2025/07/31

28.

Fidelity Advisor Equity Growth I

(0.288%)

since

2025/07/31

29.

FAST - Global Fund I-PF-ACC-USD

(0.2816%)

since

2025/05/31

30.

Fidelity Contrafund Commingled Pl S

(0.2663%)

since

2025/07/31

31.

BlackRock Health Sciences Opps Inv A

(0.2657%)

since

2025/07/31

32.

Fidelity VIP Growth Initial

(0.2554%)

since

2025/07/31

33.

BGF World Healthscience A2

(0.2527%)

since

2025/05/31

34.

Stt Strt World Dev ex US Idx SL SF Cl I

(0.2509%)

since

2025/08/31

35.

American Funds New World A

(0.218%)

since

2025/06/30

36.

Capital Group New Geography Equity Comp

(0.218%)

since

2025/06/30

37.

Blackrock EAFE Eq Idx Fund CF

(0.2145%)

since

2025/08/31

38.

Allspring All Cap Growth Equity

(0.2045%)

since

2025/06/30

39.

Allspring Growth SMA

(0.2045%)

since

2025/06/30

40.

Janus Henderson Global Life Sciences

(0.194%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.78

EPS Estimate

0.67

EPS Difference

0.11

Surprise Percent

16.4179%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.